Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...

The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.

It’s important to maintain a temperature of 77 degrees or cooler, and above freezing, so efficacy is highest when the product ...

Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...

In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...